blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4161563

EP4161563 - TREATMENT OF CD30-POSITIVE CANCER [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  10.03.2023
Database last updated on 02.09.2024
FormerThe international publication has been made
Status updated on  10.12.2021
Formerunknown
Status updated on  18.06.2021
Most recent event   Tooltip13.04.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Tessa Therapeutics Ltd.
138 Depot Road 07-01
Singapore 109683 / SG
For all designated states
The University of North Carolina at Chapel Hill
109 Church Street
Chapel Hill, North Carolina 27516 / US
[2023/15]
Inventor(s)01 / MYO, Aung
Singapore 109683 / SG
02 / HORAK, Ivan David
Singapore 109683 / SG
03 / SERODY, Jonathan
Chapel Hill, North Carolina 27516 / US
04 / DOTTI, Gianpietro
Chapel Hill, North Carolina 27516 / US
05 / SAVOLDO, Barbara
Chapel Hill, North Carolina 27516 / US
 [2023/15]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2023/15]
Application number, filing date21730909.504.06.2021
[2023/15]
WO2021EP65037
Priority number, dateUS202063035104P05.06.2020         Original published format: US 202063035104 P
[2023/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021245249
Date:09.12.2021
Language:EN
[2021/49]
Type: A1 Application with search report 
No.:EP4161563
Date:12.04.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 09.12.2021 takes the place of the publication of the European patent application.
[2023/15]
Search report(s)International search report - published on:EP09.12.2021
ClassificationIPC:A61K39/00, A61K31/41
[2023/15]
CPC:
A61K45/06 (EP); A61K39/464417 (US); A61K31/4184 (EP,US);
A61K31/7076 (EP,US); A61K39/4611 (EP,US); A61K39/4622 (US);
A61K39/4631 (EP,US); A61K39/464411 (US); A61K39/464429 (EP);
A61P35/00 (EP,US); C07K14/7051 (EP,US); C07K14/70521 (US);
C07K14/70578 (US); A61K2239/31 (EP); A61K2239/38 (EP);
A61K2239/48 (EP); C07K2317/53 (US); C07K2319/02 (US);
C07K2319/03 (US) (-)
C-Set:
A61K31/4184, A61K2300/00 (EP);
A61K31/7076, A61K2300/00 (EP);
A61K39/464429, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/15]
TitleGerman:BEHANDLUNG VON CD30-POSITIVEM KREBS[2023/15]
English:TREATMENT OF CD30-POSITIVE CANCER[2023/15]
French:TRAITEMENT DU CANCER CD30 POSITIF[2023/15]
Entry into regional phase23.12.2022National basic fee paid 
23.12.2022Designation fee(s) paid 
23.12.2022Examination fee paid 
Examination procedure23.12.2022Examination requested  [2023/15]
23.12.2022Date on which the examining division has become responsible
21.08.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
30.10.2023Amendment by applicant (claims and/or description)
Request for further processing for:30.10.2023Request for further processing filed
30.10.2023Full payment received (date of receipt of payment)
Request granted
06.11.2023Decision despatched
30.10.2023Request for further processing filed
30.10.2023Full payment received (date of receipt of payment)
Request granted
06.11.2023Decision despatched
Fees paidRenewal fee
31.03.2023Renewal fee patent year 03
12.04.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2015028444  (UNIVERSITÄT ZU KÖLN [DE]) [Y] 16-26* page 4, line 5 - line 30; sequence 3 *;
 [X]US2020016199  (TURTLE CAMERON J [US], et al) [X] 1-3,5,6,9,10,12,13 * page 1, paragraphs 0004, 0006, 0010 * * page 2, paragraph 17 * * page 3, paragraph 28 * * page 12, paragraphs 0102, 0104 *;
 [XY]  - GROVER NATALIE S ET AL, "A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+ Lymphomas", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, (2019), vol. 25, no. 3, doi:10.1016/J.BBMT.2018.12.149, ISSN 1083-8791, XP085593890 [X] 1-15 * Abstract 83 * [Y] 16-26

DOI:   http://dx.doi.org/10.1016/j.bbmt.2018.12.149
 [XD]  - RAMOS CARLOS A ET AL, "CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, (201903), vol. 25, no. 3, doi:10.1016/J.BBMT.2018.12.145, ISSN 1083-8791, XP085593886 [XD] 1-3,5,6,9,10,12,13 * Abstract 79 *

DOI:   http://dx.doi.org/10.1016/j.bbmt.2018.12.145
by applicantWO03059282
 WO2004010957
 WO2005001038
 US2005009769
 WO2006089232
 WO2007044616
 US2007166309
 WO2007084672
 US2007258987
 WO2011041093
 WO2012031744
 WO2015028444
 WO2016008973
 WO2020068764
    - RAMOS et al., J Clin Invest, (20170000), vol. 127, no. 9, pages 3462 - 3471
    - RAMOS et al., Biol Blood Marrow Transplant, (20190000), vol. 25, pages S7 - S75
    - VAN DER WEYDEN et al., Blood Cancer Journal, (20170000), vol. 7, page e603
    - MUTAPODACK, Immunol. Res., (20130000), vol. 57, no. 1-3, pages 151 - 8
    - "UniProt", Database accession no. P28908-3
    - MUTAPODACK, Immunol Res, (20130000), vol. 57, no. 1-3, pages 151 - 158
    - FALINI et al., Blood, (19950000), vol. 85, no. 1, pages 1 - 14
    - YOUNESANSELL, Semin Hematol, (20160000), vol. 53, pages 186 - 189
    - KEUDELL, British Journal of Haematology, (20190000), vol. 184, pages 105 - 112
    - KARANTANOS et al., Blood Lymphat Cancer, (20170000), vol. 7, pages 37 - 52
    - ALINARI, Blood, (20160000), vol. 127, pages 287 - 295
    - FLERLAGE et al., Blood, (20180000), vol. 132, pages 376 - 384
    - KELLY, Blood, (20150000), vol. 126, pages 2452 - 2458
    - MOSKOWITZ, ASCO Educational Book, (20190000), pages 477 - 486
    - CASTELLINO et al., Blood, (20110000), vol. 117, no. 6, pages 1806 - 1816
    - DOTTI et al., Immunol Rev, (20140000), vol. 257, no. 1
    - KAHLON et al., Cancer Res, (20040000), vol. 64, no. 24, pages 9160 - 9166
    - HOMBACH et al., J Immunol, (20010000), vol. 167, no. 1, pages 6123 - 6131
    - HOMBACH et al., Cancer Res., (19980000), vol. 58, no. 6, pages 1116 - 9
    - SAVOLDO et al., Blood, (20070000), vol. 110, no. 7, pages 2620 - 30
    - HOMBACH et al., Mol Ther, (20160000), vol. 24, pages 1423 - 1434
    - REVERDATTO et al., Curr Top Med Chem., (20150000), vol. 15, no. 12, pages 1082 - 1101
    - BOERSMA et al., J Biol Chem, (20110000), vol. 286, pages 41273 - 85
    - EMANUEL et al., Mabs, (20110000), vol. 3, pages 38 - 48
    - CARTER, Nat. Rev. Immunol, (20060000), vol. 6, pages 343 - 357
    - HOMBACH et al., Scand J Immunol, (19980000), vol. 48, no. 5, pages 497 - 501
    - SCHLAPSCHY et al., Protein Engineering, Design and Selection, (20040000), vol. 17, no. 12, pages 847 - 860
    - FORERO-TORRES et al., Br J Haematol, (20090000), vol. 146, pages 171 - 9
    - ANSELL et al., J Clin Oncol, (20070000), vol. 25, pages 2764 - 9
    - CARDARELLI et al., Clin Cancer Res, (20090000), vol. 15, no. 10, pages 3376 - 83
    - CHOTHIA et al., J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - RETTER et al., Nucl. Acids Res., (20050000), vol. 33, pages D671 - D674
    - KROGH et al., J Mol Biol, (20010000), vol. 305, pages 567 - 580
    - CHENFLIES, Nat Rev Immunol, (20130000), vol. 13, no. 4, pages 227 - 242
    - KOFLER et al., Mol. Ther., (20110000), vol. 19, no. 4, pages 760 - 767
    - HOMBACH et al., Gene Therapy, (20100000), vol. 17, pages 1206 - 1213
    - PETERSEN et al., Nature Methods, (20110000), vol. 8, pages 785 - 786
    - FRANKSIPPL, Bioinformatics, (20080000), vol. 24, pages 2172 - 2176
    - CHEN et al., Adv Drug Deliv Rev, (20130000), vol. 65, no. 10, pages 1357 - 1369
    - HOMBACH et al., Cancer Res, (19980000), vol. 58, no. 6, pages 1116 - 9
    - HOMBACH et al., Gene Therapy, (20000000), vol. 7, pages 1067 - 1075
    - HOMBACH et al., J Immunother, (19990000), vol. 22, no. 6, pages 473 - 80
    - HOMBACH et al., Cancer Res, (20010000), vol. 61, pages 1976 - 1982
    - KOEHLER et al., Cancer Res, (20070000), vol. 67, no. 5, pages 2265 - 2273
    - DI STASI et al., Blood, (20090000), vol. 113, no. 25, pages 6392 - 402
    - CHMIELEWSKI et al., Gene Therapy, (20110000), vol. 18, pages 62 - 72
    - GILHAMABKENPULE, Trends in Mol. Med., (20120000), vol. 18, no. 7, pages 377 - 384
    - CHMIELEWSKI et al., Gene Therapy, (20130000), vol. 20, pages 177 - 186
    - HOMBACH et al., Mol. Ther., (20160000), vol. 24, no. 8, pages 1423 - 1434
    - RAMOS et al., J. Clin. Invest., (20170000), vol. 127, no. 9, pages 3462 - 3471
    - MAUS et al., Annu Rev Immunol, (20140000), vol. 32, pages 189 - 225
    - WANGRIVIERE, Mol Ther Oncolytics, (20160000), vol. 3, page 16015
    - SOMERVILLEDUDLEY, Oncoimmunology, (20120000), vol. 1, no. 8, pages 1435 - 1437
    - SIMMONSALBEROLA-ILA, Methods Mol Biol, (20160000), vol. 1323, pages 99 - 108
    - KOH et al., Molecular Therapy - Nucleic Acids, (20130000), vol. 2, page e114
    - FULCHERWONG, Immunol Cell Biol, (19990000), vol. 77, no. 6, pages 559 - 564
    - BUCK et al., Biotechniques, (20080600), vol. 44, no. 7, pages 927 - 9
    - SALIMITCHISON, PNAS USA, (20080219), vol. 105, no. 7, pages 2415 - 2420
    - ZARITSKAYA et al., Expert Rev Vaccines, (20110000), vol. 9, no. 6, pages 601 - 616
    - KLEBANOFF et al., Trends Immunol, (20050000), vol. 26, no. 2, pages 111 - 7
    - MURANSKI et al., Nat Clin Pract Oncol, (20060000), no. 12, pages 668 - 81
    - CHESON et al., J Clin Oncol, (20140000), vol. 32, pages 3059 - 3068
    - SODING, J, Bioinformatics, (20050000), vol. 21, pages 951 - 960
    - NOTREDAME et al., J. Mol. Biol., (20000000), vol. 302, no. 2000, pages 205 - 217
    - LASSMANNSONNHAMMER, BMC Bioinformatics, (20050000), vol. 6, no. 298
    - KATOHSTANDLEY, Molecular Biology and Evolution, (20130000), vol. 30, no. 4, pages 772 - 780
    - GOTTESMAN, Pathology and Laboratory Medicine International, (20160000), vol. 8, pages 27 - 36
    - HOELLER et al., Histopathology, (20100000), vol. 56, pages 217 - 228
 US20040630351
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.